Recent studies have demonstrated that P2Y12-inhibitor monotherapy is potentially superior to acetylsalicylic acid monotherapy for long-term secondary prevention in patients with coronary artery disease [27,58]. The gene discussed is P2RY12; the disease is coronary artery disorder.